Trial Profile

A Randomized, Subject and Investigator Blinded, Placebo-controlled and Multi-center Platform Study, to Assess Efficacy and Safety of Different Investigational Drugs in Patients With Moderate to Severe Hidradenitis Suppurativa

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 30 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Iscalimab (Primary) ; LYS-006 (Primary) ; MAS 825 (Primary) ; Remibrutinib (Primary)
Indications Hidradenitis suppurativa
Focus Therapeutic Use
Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals

28 Feb 2025 According to a Novartis media release, Company will present data from this study at the 2025 American Academy of Dermatology (AAD) Annual Meeting.
03 Jan 2025 Planned End Date changed from 23 Nov 2026 to 10 Dec 2026.
27 Aug 2024 Planned End Date changed from 23 Oct 2026 to 23 Nov 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com